Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
https://www.jci.org/articles/view/172887
https://journals.sagepub.com/doi/abs/10.1177/14550725241253362
https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1443304
Addict Behav.gif
elsevier.jpg Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial
Christina McAnulty, Gabriel Bastien, Omar Ledjiar, M. Eugenia Socias, Bernard Le Foll, Ron Lim, Didier Jutras-Aswad
The relationship between opioid craving and opioid use is unclear. We sought to determine to what extent craving mediated the relationship between opioid agonist therapy and…
https://onlinelibrary.wiley.com/doi/absfull/10.1111/hiv.13636
LargeRollover.01271255-202403000-00000.CV.jpeg
Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study
Hamzah Bakouni, Lexie Haquet, Eugenia Socias, Bernard Le Foll, Ron Lim, Keith Ahamad, Didier Jutras-Aswad, for the OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse
Methadone and buprenorphine/naloxone (BUP/NX) titration parameters (eg, range, duration, and rate) can vary during opioid use disorder (OUD) treatment. We describe methadone and BUP/NX titration patterns and their associations with treatment…
wjdd_a_2329267_f0002_c.jpg
TandF.png Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
Gabriel Bastien, Anita Abboud, Christina McAnulty, Laurent Elkrief, Omar Ledjiar, Eugenia Socias, Bernard Le Foll, Anees Bahji, Suzanne Brissette, Stéphanie Marsan, DidierJutras-Aswad
showCoverImage.jfif
TandF.png Cannabis Use Characteristics Associated with Self-Reported Cognitive Function in a Nationally Representative U.S. sample
Dafna Sara Rubin-Kahana, Kevin Butler, Ahmed Nabeel Hassan, Marcos Sanches, Bernard Le Foll
With increases in cannabis use and potency, there is a need to improve our understanding of the impact of use on cognitive function. Previous research indicates long-term cannabis use may have a negative effect on executive function. Few studies have examined persistence of it in protracted abstinence…
https://doi.org/10.1186/s42238-024-00234-y
http://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-2264-1047
Book.jpg

elsevier.jpg Cannabis use in the COVID-19 pandemic: Changes in different populations and implications for policy in Linking Neuroscience and Behavior in COVID-19
Created by Adam Zaweel, Isaac Kuk, Soyeon Kim, Bernard Le Foll, Christine Wickens.

https://www.mdpi.com/2076-3425/14/4/356
CaptureSUM.PNG
TandF.png Participant Fraud in Virtual Qualitative Substance Use Research: Recommendations and Considerations for Detection and Prevention Based on a Case Study
Created by Madison Wright, Justin Matheson, Tara Marie Watson, Beth Sproule, Bernard Le Foll, Bruna Brands
The COVID-19 pandemic has accelerated and amplified the use of virtual research methods. While online research has several advantages, it also provides greater opportunity for individuals
https://www.mdpi.com/2076-3425/14/3/246
https://journals.sagepub.com/doi/full/10.1177/07067437231210796
Can J.jpg
Sage.png The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial
Created by Anees Bahji, Gabriel Bastien, Paxton Bach, JinCheol Choi, Bernard Le Foll, Ron Lim, Didier Jutras-Aswad & M. Eugenia Socias.
Prescription-type opioid use disorder (POUD) is often accompanied by comorbid anxiety, yet the impact of anxiety on retention in opioid agonist therapy (OAT) is unclear. Therefore, this study investigated…
Clin Pharm.jpg
ASCPT.png Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone
Created by Intishar Kazi, Meghan Chenoweth, Didier Jutras-Aswad, Keith Ahamad, M. Eugenia Socias, Bernard Le Foll, Rachel Tyndale
Methadone and buprenorphine/naloxone are opioid agonist therapies for opioid use disorder treatment. Genetic factors contribute to individual differences in opioid response…
https://doi.org/10.1186/s12906-023-04312-1
https://doi.org/10.1001/jamanetworkopen.2023.52233
https://doi.org/10.1016/j.brs.2024.01.008
add.v119.2.cover.jpg
Wiley.jpg Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials
Created by Heidar Sharafi, Hamzah Bakouni, Christina McAnulty, Sarah Drouin, Stephanie Coronado-Montoya, Arash Bahremand, Paxton Bach, Nadine Ezard, Bernard Le Foll…
There is currently no standard of care for pharmacological treatment of amphetamine-type stimulant (ATS) use disorder (ATSUD). This systematic review with meta-analysis (PROSPERO CRD42022354492) aimed to pool results from randomized placebo-controlled trials (RCTs) to evaluate efficacy and safety of prescription psychostimulants (PPs) for ATSUD…
https://www.cmaj.ca/content/196/6/E187
Expand
titleMore from Bernard Le Foll

2023